Technology evaluation: transgenic antithrombin III (rhAT-III), Genzyme Transgenics.
Author(s): Yeung PK
Affiliation(s): College of Pharmacy, Dalhousie University, Halifax, NS B3H-3JS, Canada. pyeung@kilcom1.UCIS.Dal.CA
Publication date & source: 2000-06, Curr Opin Mol Ther., 2(3):336-9.
Publication type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Randomized Controlled Trial
AT-III LLC, a joint venture between Genzyme Transgenics (GTC) and Genzyme General, is developing transgenic recombinant human antithrombin III (rhAT-III) as a potential treatment for sepsis and other disorders involving thrombosis. It is in phase III clinical trials in the US and Europe as an anticoagulant in patients undergoing elective cardiac surgery such as cardiopulmonary bypass.
|